The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...
AstraZeneca (AZN) announced on Wednesday that the U.S. Food and Drug Administration has delayed a review of its marketing ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
AstraZeneca said the U.S. Food and Drug Administration is pushing back its decision on whether to approve a new breast-cancer drug in order to review additional data provided by the company. The U.K.
Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.
17h
AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock
An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...
(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy ...
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca’s experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results